Patient-centric genomics company DxTerity announced it will collaborate with California-based City or Hope Medical Center on the clinical development of a blood test intended to predict whether patients about to undergo radiation therapy for cancer are likely to benefit from the treatment. The test will also seek to provide information…

The more diverse the digestive tract bacteria, the slower the progression of metastatic melanoma in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center reported today. At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the researchers presented results from a…

On the afternoon of January 21, 2016, Clinical OMICS magazine sponsored a webinar to discuss what is currently the hottest topic in the field of molecular diagnostics and possibly all of clinical medicine—liquid biopsy. In the December issue, we discussed how this cutting-edge test was able to capture noninvasively minute…

Clinical medicine stands at the threshold of a diagnostic revolution. At the current pace, advances in next-generation sequencing and molecular diagnostics could render the use of invasive techniques for prognostic analysis obsolete within a decade. Development of novel methods for capturing circulating tumor cells (CTCs) and tumor DNA (ctDNA), smartly…

Cynvenio Biosystem and ATGen Global are poised to bring ATGen’s NK Vue™ test to the U.S. market, as a result of a collaborative partnership. NK Vue is an ELISA-based blood test that measures Natural Killer (NK) cell activity. NK cells are part of the innate immune system and represent the…

One of the main goals of personalized medicine is the ablity to quickly and accurately determine the genetic background of a patient and prescribe the appropriate therapy based on their mutational signature. To address this vital component of modern medicine initiatives, researchers have designed a new form of clinical trial,…